The Drug

Corifungin

Corifungin is a small-molecule, water-soluble anti-fungal drug. It is a water-soluble polyene macrolide and can be administered intravenously, orally or topically. Corifungin is a broad-spectrum antifungal drug. In vitro and in vivo testing has shown it to efficacious against a wide range of fungal diseases including Candida, Aspergillius, Coccidioides (Valley Fever), Blastomycese dermatitidis, Histoplasma capsulatum, Paracoccidioides brasiliensis as well as vulvovaginal candidiasis, and onychomycosis (toe fungus).

Treatment of Fungal Infections

Corifungin attacks the fungi cell wall and breaks the cycle of growth.

Currently, Amphotericin B is the “gold standard” for anti-fungal drugs. However, the main drawback of Amphotericin B is its insolubility into water which causes it to lodge in the kidney and cause nephrotoxicity. The second best class of antifungal drugs are the azoles, but their drawbacks include unfavorable interaction when administered with other drugs, and a fungistatic mode of action which makes them prone to fungal resistance.

Corifungin is efficacious against the following fungi:

Candida albicans
Candida glabrata
Candida parapsilosis
Candida tropicalis
Candida krusei
Candida lusitaniae
Candida kefyr
Aspergillus fumigateurs
Aspergillus niger
Aspergillus glaucus
Aspergillus terreus
Aspergillus flavus
Aspergillus versicolor
Coccidioides
Blastomyces dermatitidis
Histoplasma capsulatum
Paracoccidioides brasiliensis
Alternaria sp
Cladosporium
Scopulariopsis
Acremonium
Paecilomyces
Emmonsia parvum
E. Jeanselmei
Epioccum spp.

Treatment of Amebic Diseases

Corifungin has been shown to be effective against certain rare diseases. The Company has partnered with James McKerrow, Ph.D., M.D., Head of Rare Diseases at the University of California, San Francisco. Dr. McKerrow has extensively explored the treatment of amebic diseases. In his work with Acea Biotech, he tested multiple organisms and found efficacy against Naegleria fowleri which causes Primary Amoebic Meningoencephalitis (“PAM”) and Visceral leishmaniasis. Acea applied for, and was granted “orphan drug status” for both indications from the FDA.